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Abstract Glucocorticoid-induced osteoporosis (GIOP) is
one of the most important side effects of glucocorticoid use,
as it leads to an increased risk of fractures. Recently, many
published studies have focused on the cellular and molecular
mechanisms of bone metabolism, the pathophysiology of
GIOP, and the intervention options to prevent GIOP. In this
review, recent advances in GIOP are summarized, particu-
larly recent progress in our understanding of the mechanisms
of GIOP resulting in improved insight that might result in the
development of new treatment options in the near future.
Keywords Bone.Glucocorticoids.Osteoporosis
Introduction
Glucocorticoids (GCs) are used frequently in a variety of
diseases because of their strong anti-inflammatory and
immunosuppressive effects. However, corticosteroids have
many metabolic side effects, such as insulin resistance,
hypertension, glaucoma, and osteoporosis. GC-induced
osteoporosis (GIOP) is one of the most devastating side
effects because bone loss during long-term GC treatment is
generally irreversible and because of its clinical manifes-
tations (eg, vertebral and nonvertebral fractures). In recent
years, considerable improvements have been made in our
understanding of the pathogenesis of GIOP. Furthermore,
new trials report beneficial effects of antiresorptive and
anabolic agents. This article reviews the current epidemi-
ology and pathophysiology of GIOP and discusses the
treatment possibilities.
Epidemiology
GCs are frequently prescribed in patients with a wide
variety of chronic diseases, such as rheumatoid arthritis,
polymyalgia rheumatica, inflammatory bowel disease, and
chronic obstructive pulmonary disease. It is estimated that
3% of the population 50 years of age and older has used
GCs, and this percentage rises to 5.2% among those
80 years of age and older [1]. Treatment with GCs results
in bone loss and increased risk of vertebral and non-
vertebral fractures [2]. Earlier data demonstrated that 30%
of patients with long-term GC use (>6 months) would
develop osteoporosis [3]. The bone loss is more pro-
nounced in the trabecular bone, which can be found
predominantly in the spine and ribs, and starts within
months after initiation of therapy [2, 4]. Earlier studies
showed that the bone loss is biphasic, with a rapid initial
phase of 3% to 5% in the first year of GC treatment,
followed by a slower phase during continued use of 0.5% to
1% annually [5, 6, 7￿￿].
Furthermore, GC use increases the risk of fractures, an
effect that appears to be dose dependent [8, 9]. Up to 30%
of patients on chronic GC treatment will have an incident
fracture [3]. The risk of vertebral fractures is particularly
elevated—two to five times, depending on the daily dosage
of prednisone; this increase occurs as soon as 3 months
after treatment has started [10]. After cessation of GC
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therefore seems to be partially reversible [11]. However, in
patientsusing high doses (>1 g), it took more than 15 months
to return to baseline fracture risk. The risk of fractures is
increased for women and men and is age dependent.
Furthermore, other determinants of bone loss, such as
smoking, immobility, and the activity of the underlying
disease, also play a role in the increased fracture risk [12].
Although there is an apparent effect of GCs on bone
density and fracture risk, the risk of fractures cannot be
explained completely by the changes in bone mineral
density (BMD). Besides bone loss, an increased fracture
risk is supposedly caused by a reduced bone quality [13].
Earlier studies have pointed toward a change (decrease) in
the so-called “bone density threshold for vertebral frac-
tures” [14, 15]. After a follow-up of 1 year, patients on GC
treatment had significantly more vertebral fractures than
controls, while their BMD values were higher.
Mechanisms of Glucocorticoid Action
In recent years, the general mechanism of GC action has
become more clear. GCs exert their actions via genomic
and nongenomic pathways. Most of their important
therapeutic effects are exerted via genomic mechanisms
by binding of the GC to cytosolic GC receptors (cGCRs).
After binding to the cGCR, the GC/glucocorticoid (GCR)
complex translocates to the nucleus, where binding to
specific transcription factors leads to induction or inhibi-
tion of transcription of certain genes, called transactiva-
tion and transrepression, respectively. The GC/GCR
complex acts directly with the transcription factors activator
protein 1 (AP-1) and nuclear factor-κB, which have an
important role in the regulation of many inflammatory
genes [16, 17]. Although most of the therapeutic effects of
GCs take place by transrepression, transactivation is
responsible for a considerable number of metabolic side
effects of GC treatment.
Apart from genomic actions, nongenomic GC mecha-
nisms can exert rapid clinical effects, which can be divided
into three distinct mechanisms [18]. First, GCs exert effects
mediated by the cGCR. The binding of GC to cGCR
promotes the release of signaling molecules, causing rapid,
non-nuclear actions. Second, GCs have effects mediated by
the recently discovered membrane-bound GC receptor.
Binding of GCs with these membrane-bound GC receptors
has been shown to alter transduction pathways within
minutes, resulting in apoptosis of the cell. Finally, at very
high dosages, unspecific effects are caused by physico-
chemical interactions between GCs and the cellular mem-
brane. GCs influence ion transport of plasma cells via direct
contact with the cell membrane, and direct contact with the
mitochondrial membranes causes proton leakage.
Effects of Glucocorticoids on Bone and Fracture Risk
Earlier data on the pathogenesis of GIOP were mainly
based on histomorphometric data derived from patients
treated with high-dose GCs without protective anti-
osteoporotic drugs such as bisphosphonates. In these
histomorphometric studies, reduced bone formation was
observed, characterized by a low mineral apposition rate,
which is related to reduced numbers of osteoblasts, while
bone resorption was unchanged or even elevated [19].
During the past few years, several studies have provided
more understanding of the molecular mechanisms involved
in GIOP (Fig. 1), which are discussed in more detail below.
These include the increased apoptosis of osteoblasts and
osteocytes, impaired differentiation of osteoblasts, and
increased life span of osteoclasts.
It has been known for several years that GCs induce
apoptosis of osteoblasts and osteocytes. The increased
apoptosis of osteoblasts results in a significant reduction
in bone formation, and it has been postulated that the loss
of osteocytes results in a disrupted osteocyte–canalicular
network and failure to respond to bone damage [20]. This
Fig 1 Pathophysiology of
glucocorticoid-induced effects
on bone cells. BMP—bone
morphogenetic protein;
Dkk-1—dickkopf-1; GSK3β—





for nuclear factor-κB ligand;
Runx2—runt-related protein 2
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mechanism of osteoblast and osteocyte apoptosis was not
fully elucidated. Recent data show that GCs induce
apoptosis of osteoblasts and osteocytes by activating
caspase-3 [21]. Furthermore, apoptosis of osteoblasts was
recently found to be related to the activation of glycogen
synthase kinase 3β (GSK3β), which plays a role in the Wnt
signaling pathway [22]. The Wnt signaling pathway is
important in bone metabolism and especially osteoblasto-
genesis. Normally, binding of Wnt to the low-density
lipoprotein receptor–related protein 5 and 6 (LRP5/6) and
its co-receptor, frizzled, stabilizes β-catenin, which leads to
transcription of target genes and subsequent induction of
bone formation. GCs have been shown to suppress this
pathway by increasing the production of Wnt pathway
inhibitors, such as dickkopf-1 (Dkk-1) [23, 24].
In addition to increased apoptosis of osteoblasts, GCs
impair osteoblast function via several pathways. GCs were
recently shown to interfere with both the bone morphoge-
netic protein pathway and the Wnt signaling pathway,
thereby inhibiting osteoblast differentiation [25]. As men-
tioned previously, GCs have been shown to suppress the
Wnt signaling pathway by increasing the production of
Dkk-1 [23, 24]. Interestingly, silencing Dkk-1 abrogates the
GC-induced suppression of osteoblast differentiation [26].
Furthermore, GCs were recently shown to stimulate
bone marrow stromal cells—the precursor cells of osteo-
blasts—to differentiate toward adipocytes instead of osteo-
blasts. This is mainly mediated through an increased
expression of the peroxisome proliferator-activated
receptor-γ2 and repression of the osteogenic transcription
factor runt-related protein 2 [27]. Recent research suggested
that high doses of GCs cause a shift toward adipogenesis
via repression of AP-1. Thus, transrepression of AP-1 not
only mediates anti-inflammatory actions but also yields
reduced bone strength [28].
In contrast to increased apoptosis of osteoblasts and
osteocytes, the apoptosis of osteoclasts is reduced during
GC treatment. The life span of osteoclasts is extended due
to an upregulation of receptor activator for nuclear factor-
κB ligand (RANKL) and suppression of osteoprotegerin
(OPG) [29]. The GC-mediated suppression of OPG could
occur through the Wnt signaling pathway [30]. However,
this prolonged life span of osteoclasts may be associated
with reduced function. A recent in vitro study showed that
direct effects of GCs on osteoclasts result in a suppressed
capacity for bone resorption. Such direct effects include, for
example, interference with the formation of ruffled border
and disruption of the cytoskeleton [31].
Besides direct effects on osteoblasts, osteocytes, and
osteoclasts, GCs exert indirect effects on bone. It has been
known for a long time that GCs impair bone metabolism
via inhibition of calcium resorption in the gastrointestinal
tract and inhibition of the renal tubular calcium reabsorp-
tion, which may lead to hypocalcemia and a tendency
toward hyperparathyroidism. Recently, GCs have been
s h o w nt oi n f l u e n c et h eb o n em i n e r a l i z a t i o nb yt r a n s -
repression of osteocalcin and collagen I, two important
proteins of the matrix [32]. Furthermore, GCs may
indirectly increase fracture risk via an enhanced risk of
falling caused by steroid myopathy [4].
Management of Glucocorticoid-Induced Osteoporosis
General Measures
First, efforts should be made to prescribe GCs in the lowest
possible doses and for a short period of time when possible.
Patients receiving GC treatment should be advised to stop
smoking and limit alcohol intake and should be stimulated
to have a sufficient calcium intake and to perform weight-
bearing activities daily. Furthermore, an assessment of fall
risk is recommended in these patients, who are theoretically
at increased risk of falling due to steroid myopathy; a
variety of approaches are available [33].
Calcium and vitamin D supplementation have been proven
to be essential in the management of GIOP. Patients are
advised to have a total calcium intake of at least 1,000 to
1,200 mg/d. An adequate vitamin D level is necessary, and a
minimum serum level of greater than 50 nmol/L 25(OH)D3 is
advised during the whole year [34]. Vitamin D supplemen-
tation in doses of at least 800 IU/d are recommended to
achieve these therapeutic levels. However, in some patients,
higher doses are needed, probably because some GC users
do not go outside often and because it is suggested that GCs
interfere with vitamin D absorption. Calcium and vitamin D
supplementation are shown to more or less stabilize BMD in
patients on chronic GC treatment [35].
Fracture Risk
As discussed previously, the pathophysiology of osteopo-
rotic fragility fractures during GC treatment is multifacto-
rial, as it includes bone- and fall-related factors and is also
strongly related to baseline risk. Identifying patients with
increased fracture risk solely using bone mass measure-
ments has several disadvantages and shortcomings, such as
its age dependency and its inaccuracy in measuring bone
quality. Therefore, it has been recommended that fracture
risk should be assessed using models that calculate the
absolute fracture risk for the individual patient. The
disadvantage of using the absolute fracture risk is the lack
of consensus regarding when exactly treatment should be
initiated. Therefore, any cutoff point will be arbitrary.
Several algorithms are presently available to determine how
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dosage of prednisone and on the T-score of BMD measure-
ments of the hip and spine. First, the General Practice
Research Database, also known as FIGS (Fracture in GIOP
Score), has been developed [9]. This model calculates the
5- and 10-year risk of an osteoporotic fracture of the hip,
vertebrae, and wrist. The use of this model is somewhat
complicated, but this scoring method has the advantage that
the underlying disease, the GC dosage, and the fall risk are
taken into account. Another frequently used model is the
Fracture Risk Assessment (FRAX) tool as proposed by the
World Health Organization [36]. This model is unique in
that it takes into account the family history and the BMD
but excludes the evaluation of the risk factors of falls and
the presence or absence of prevalent vertebral deformities,
although they are recognized as a risk factor for fractures.
Furthermore, GC usage, but not dosage, is recorded in this
model. The 10-year fracture risk can be calculated easily on
the Internet. Besides being useful in treatment decisions,
the assessment of fracture risk may also be useful in
improving a patient’s treatment adherence, as it gives the
patient a better insight into his or her future fracture risk
and into the degree of risk reduction once treatment with
anti-osteoporotic drugs is initiated.
Medication
Bisphosphonates have been shown to be effective in
preventing GC-induced bone loss in several randomized
controlled trials (Table 1)[ 5, 6, 37–41]. Alendronate
improved lumbar spine BMD in patients on long-term
GCs after 1 year, while the BMD decreased in patients
receiving placebo [39]. After 2 years, this difference was
sustained [5]. Interestingly, the greatest increase in BMD
occurred within the first year. Two trials addressed the
efficacy of risedronate in preventing GC-induced bone
loss [6, 38]. One study included patients starting with GCs
and found that risedronate prevented bone loss. The other
study included patients on long-term GC treatment and
showed that risedronate increased the BMD. The average
difference in percentage of BMD change among patients
using bisphosphonates was plus 4.6% compared with
patients using placebo/calcium [37]. Adding vitamin D
supplementation to bisphosphonate treatment further en-
Table 1 Treatment effects on BMD and incident vertebral fractures in GIOP
Intervention Comparative Patients, n Design Duration Change in BMD,% Change in BMD,% Vertebral fractures
Spine Fem neck Placebo Study drug
Placebo Med Placebo Med
Risedronate [6] Placebo 224 Prevention 1 year -2.8 +0.6
a -3.1 +0.8
a 9/52 (17.3%) 3/53 (5.7%)
Risedronate [38] Placebo 290 Treatment 1 year +0.4 +2.9
a -0.3 +1.8
b 9/60 (15%) 3/60 (5%)
Risedronate
c [41] Placebo 518 Both 1 year -1.0 +1.9
a -1.5 +1.3
a 18/111 (16.2%) 6/111 (5.4%)
b
Alendronate [39] Placebo 477 Treatment 1 year -0.4 +2.9
a -1.2 +1.0
a 8/135 (5.9%) 8/268 (2.9%)
Alendronate [5] Placebo 477 Treatment 2 years -0.8 +3.9
a -2.9 +0.6
b 4/59 (6.8%) 1/143 (0.7%)
d
Alendronate [40] Placebo 173 Treatment 1 year -0.6 +2.5
a +0.1 +0.4 ––
Zoledronic acid [7] Risedronate 545 Treatment 1 year +2.7 +4.1
e +1.5 +0.4
a 5/833 (0.6%) 3/833 (0.4%)
288 Prevention +2.0 +2.6
e +1.3 -0.03
a




Strontium ranelate No data –––– – – – – –
Teriparatide [44] Alendronate 428 Treatment 18 months +3.4 +7.2
a –– 10/165 (6%) 1/171 (0.6%)
f
Teriparatide [45￿￿] Alendronate 428 Treatment 36 months +5.3 +11.0
a +3.4 +6.3
a 13/169 (7.7%) 3/173 (1.7%)
g
PTH (1-84) No data –––– – – – – –
aP≤0.001
bP≤0.01





BMD bone mineral density, Fem femoral neck, GIOP glucocorticoid-induced osteoporosis, Med medication, PTH parathyroid hormone
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plus 6%.
Furthermore, for both alendronate and risedronate, a
reduction in vertebral fractures has been observed in random-
ized controlled trials involving patients treated with GCs [5,
41]. Alendronate reduced vertebral fracture risk compared
with placebo after 2 years of follow-up: the incidence of
morphometric vertebral fractures in patients treated with
alendronate was 0.7%, compared with 6.8% in placebo-
treated patients (P=0.026) [5]. No reduction in nonvertebral
fractures was observed (incidental fractures, 9.8% vs 5.4%
[placebo vs alendronate]). Similarly, a 70% reduction in
vertebral fracture risk was found for risedronate as compared
with placebo [41]. Again, no significant difference was noted
in the incidence of nonvertebral fractures. Recently, zole-
dronic acid, given yearly by intravenous infusion, was
shown to prevent GIOP [7￿￿]. In this randomized controlled
trial, zoledronic acid was not compared with placebo, but
ratherwithanactivecomparator:dailyrisedronate.Zoledronic
acid was found to be more effective than risedronate in both
the treatment (zoledronic acid, +4.06% spine BMD vs
risedronate, +2.71% spine BMD) and prevention subgroups
(zoledronic acid, +2.6% spine BMD vs risedronate, +0.64%
spine BMD) after 12 months of treatment. In this trial, no
statistically significant difference in fracture rate was ob-
served. Obviously, this is related to the fact that in this trial, a
comparison with an anti-osteoporotic drug, not placebo, was
performed. The larger increase in BMD in the zoledronate
group is difficult to interpret because it is not known whether
thelargerincreaseinBMDisalsoreflectedinalargerincrease
in bone strength and/or a larger reduction in fracture rate.
Zoledronic acid should be given by intravenous infusion,
which may have some practical considerations and an impact
on hospital budget (depending on the health system of each
specific country). In addition, the risk of renal damage is
higher in patients with compromised kidney function (eg, in
older adult patients with moderate kidney function and a
superimposed infection), leading to dehydration. The effects
of ibandronate were recently studied in men after cardiac
transplantation. All men received GCs directly after trans-
plantation, and the mean cumulative dose of cortisone was
1 7ga f t e r1y e a r .M e nw e r er a n d o m l ya s s i g n e dt oi b a n d r o n a t e
or placebo, and after 1 year, spine BMD remained unchanged
in the men treated with ibandronate, compared with a decline
in spine BMD (-25%) in patients treated with placebo.
Furthermore, there was a significant difference in number
of morphometric vertebral fractures (ibandronate, 13% vs
placebo, 53%) [42]. Thus, ibandronate prevents bone loss
and vertebral fractures in cardiac transplantation patients
on immunosuppressive therapy, including GCs. No data
are available on the effects of strontium ranelate and
parathyroid hormone (PTH) 1-84 with respect to the
prevention of GIOP.
Because the effect of GCs is dominated by their
inhibiting effect on bone formation, it is theoretically more
or less unexpected that antiresorptive drugs (eg, bisphospho-
nates) will be useful in GC-treated patients. Recently, the
mechanism of bone loss prevention by bisphosphonates has
become more clear. Experimental studies demonstrated that
bisphosphonates lower the expression of genes that inhibit
the mineralization, thereby increasing trabecular bone
volume [43]. Theoretically, anabolic agents should be the
first choice in GC-treated patients, based on the pathogen-
esis of GIOP. Clinical studies show that PTH 1-34
(teriparatide) is more effective in preventing GIOP than
bisphosphonates. Recently, the anabolic agent teriparatide
was compared with the active comparator alendronate in
428 women and men with osteoporosis who received GCs
(>5 mg/d) for at least 3 months [44]. After 18 months, the
BMD in the lumbar spine increased significantly more in
patients receiving teriparatide than in patients receiving
alendronate (7.2% vs 3.4%). Remarkably, a difference in
the number of patients with new vertebral fractures was
observed as well: 0.6% in the teriparatide group versus
6.1% in the alendronate group (P=0.004). In line with other
studies, no difference was found in nonvertebral fracture
rate. This finding was confirmed in the follow-up study
during another 18 months of treatment [45￿￿]. Interestingly,
treatment with teriparatide not only reduced fracture rate
but was also shown to reduce back pain and to improve
quality of life [46]. No data are available for PTH 1-84 in
GC-treated patients. Intervention with PTH 1-34 restored
trabecular bone volume, increased bone formation, and
increased bone strength in an animal model [43, 47]. PTH
treatment counteracts the negative effects of GCs on
osteoblast and osteocyte apoptosis. These effects were
recently demonstrated to be exerted by increasing the
expression of Wnt signaling agonists [43, 47]. Thus far,
noclearguidelinesexistregardingwhichGC-treatedpatients
should be offered teriparatide as a first-line drug. Because of
the relatively high cost of teriparatide, introduction of
teriparatide may have an impact on several budgets. In
addition, the inconvenience of injecting teriparatide may
limit its use. Nevertheless, teriparatide is attractive not only
because of its working mechanism but also because it has
been proven to be superior to bisphosphonates in GC-treated
patients. Thus, it may be attractive to prescribe teriparatide in
patients with a very high risk of fractures (eg, 10-year
absolute fracture risk>20%).
Recent studies on the molecular pathways underlying bone
metabolism have identified potential novel therapeutic targets
for the management of osteoporosis. For the future, it can be
expected that new drugs interfering with the Wnt signaling or
RANKL/OPG pathways may prove more effective than
current treatment options (eg, bisphosphonates) in reducing
GIOP. It is obvious that new anti-osteoporotic drugs for GIOP
Curr Rheumatol Rep (2011) 13:233–240 237(eg, denosumab, cathepsin K inhibitors, and monoclonal
antibody against sclerostin) should be tested against an active
comparator for ethical reasons.
Very recently, the American College of Rheumatology
recommendations for the prevention and treatment of GIOP
were updated, including renewed recommendations for
counseling and monitoring GIOP and updated pharmaco-
therapeutic interventions [48￿￿]. This update was necessary
because of new insights into the value of BMD measure-
ments in identifying patients at risk and because new
diagnostic tools and data on therapies were available. These
recommendations provide an up-to-date guideline for the
management of GIOP for two patient groups: postmeno-
pausal women and men older than 50 years of age, and
premenopausal women and men younger than 50 years of
age initiating or receiving GC therapy. The subdivision of
patients into fracture risk categories (low [<10%], medium
[10%–20%], and high [>20%]) results in clear recommen-
dations that are easy to work with in clinical practice. These
risk categories were established using the FRAX tool. The
FRAX tool is based on a large database, but as mentioned
earlier, it unfortunately does not include some important risk
factors for fractures, such as daily dose of prednisolone, the
presence or absence of prevalent vertebral fractures, and risk
of falling. Furthermore, the risk categories were defined by
an expert panel rather than based on evidence.
Adherence
Adherence to therapy is also a well-known and important
problem in GIOP. A large, retrospective database study
recently showed that after 1 year, less than 40% of patients
were adherent to treatment [49￿]. This low percentage may
be explained in several ways. First, anti-osteoporotic drugs
are prescribed for prevention of future fractures. In
comparable circumstances (eg, patients on blood pressure–
lowering drugs), nonadherence is an important issue,
whereas in patients with arthritis, adherence is usually
better because anti-inflammatory drugs induce relief of pain
and inflammation. Second, patients starting on GCs are
usually ill and are being informed about their underlying
disease, including several possible side effects of GCs, such
as hypertension, diabetes, glaucoma, infections, and osteo-
porosis. Thus, osteoporosis is just one item on the long list
of possible side effects, for which it might be necessary to
take two or three types of additional drugs. Third,
monitoring the effects of anti-osteoporotic drugs is not
optimal. The value of BMD testing to monitor therapy and
the interval of BMD testing are controversial. Changes in
bone markers occur by 2 to 3 months after initiation of
treatment with anti-osteoporotic drugs, but measurement of
bone marker values is limited in daily clinical practice
because of a relatively high analytical variation, circadian
rhythm, and costs. It is only possible in some centers that
have focused their research on biomarkers and osteoporo-
sis. Finally, (mild) gastrointestinal side effects may occur in
20% to 30% of patients, and 2 to 3 days of fever and flu-
like symptoms occur in nearly all patients treated with high-
dose bisphosphonates, causing patients to be nonadherent.
Furthermore,generalfactorsnotdirectlyrelatedtobisphospho-
nates may come into play. For example, an increased number
of prescribed drugs increases an individual’s risk of non-
adherence; anti-osteoporotic drugs are usually prescribed in
older adults, in whom adherence may be limited due to (early)
dementia; and some patients have a general negative opinion
against drugs.
Several measures to improve adherence in GIOP have
been suggested, such as the model of “shared decision
making” [50] and a specialized “GIOP outpatient clinic”
[51]. In the model of shared decision making, the patient
and physician discuss the pros and cons of starting anti-
osteoporotic drugs. It is important to realize that the
arguments used may differ between patients and physicians.
Moreover, “patients’ health-believe” is a major factor in
therapeutic compliance. Using the absolute fracture risk
may be very useful, as it gives patients better insight into
their future fracture risk and the degree of risk reduction
when treatment with anti-osteoporotic drugs is initiated.
An organized program of care called a glucocorticoid-
induced osteoporosis program, in which high fracture risk
patients were identified, educated, and intensively moni-
tored, proved to be effective in the treatment of patients on
chronic GCs [51]. Patients’ knowledge, lifestyle, and serum
vitamin D levels all significantly improved, while adher-
ence to therapy was 91%. The challenge for the future will
be the development of implementation strategies to trans-
late these care programs from highly specialized clinics to
routine daily clinical care.
Conclusions
GIOP is one of the most important causes of secondary
osteoporosis and is associated with an evident clinical
impact due to increased fracture risk. Increased apoptosis of
osteoblasts and osteocytes and increased life span of
osteoclasts leads to decreased BMD and bone strength,
and increased insight in recent years into the molecular
mechanism has suggested an important role for the
RANKL/OPG pathway and Wnt signaling route in the
pathophysiology of GIOP. To identify patients with
increased fracture risk more accurately, new tools to assess
absolute fracture risk are available. GIOP can be partially
prevented with the use of oral bisphosphonates (alendro-
nate, risdronate) and zoledronic acid. However, oral
bisphosphonates are limited by low adherence rates, and
238 Curr Rheumatol Rep (2011) 13:233–240zoledronic acid should be given intravenously. In contrast,
PTH 1-34 therapy seems to be superior to oral bisphospho-
nates but is more expensive. The recent advances in the
pathophysiology of GIOP have led to the development of
new treatment options that will be available in the (very
near) future to reduce the incidence of GIOP and improve
the quality of life of these patients.
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